Solventum Corporation $SOLV Shares Acquired by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its Solventum stake by 16,656.8% in the third quarter, acquiring 480,048 additional shares to hold 482,930 shares valued at approximately $42.6 million.
• Solventum reported quarterly results above expectations, with EPS of $2.55 versus the $1.91 consensus and revenue of $2.21 billion, up 2.2% year over year. The company issued fiscal 2026 EPS guidance of $7.10–$7.20.
• Analysts remain generally positive, with 10 Buy, three Hold and one Sell rating; the stock has a Moderate Buy consensus and an average price target of $92.80, compared with a recent price of $85.76.

Assenagon Asset Management S.A. boosted its position in Solventum Corporation (NYSE:SOLV - Free Report) by 16,656.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 482,930 shares of the company's stock after acquiring an additional 480,048 shares during the period. Assenagon Asset Management S.A. owned 0.28% of Solventum worth $42,570,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in SOLV. B. Riley Wealth Advisors Inc. lifted its stake in Solventum by 10.8% in the third quarter. B. Riley Wealth Advisors Inc. now owns 3,955 shares of the company's stock valued at $349,000 after buying an additional 386 shares during the period. Legacy Wealth Asset Management LLC bought a new position in Solventum during the third quarter worth about $207,000. GAMMA Investing LLC grew its position in shares of Solventum by 38.9% during the 3rd quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock worth $858,000 after buying an additional 2,727 shares during the period. Farther Finance Advisors LLC grew its position in shares of Solventum by 9.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 11,984 shares of the company's stock worth $1,056,000 after buying an additional 1,072 shares during the period. Finally, Westwind Capital bought a new stake in shares of Solventum in the 3rd quarter valued at about $1,645,000.

Solventum Stock Down 2.4%

Solventum stock opened at $85.76 on Friday. The company has a 50 day moving average of $88.64 and a 200-day moving average of $79.90. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $94.16. The stock has a market capitalization of $14.60 billion, a PE ratio of 10.48, a price-to-earnings-growth ratio of 1.32 and a beta of 0.63.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping analysts' consensus estimates of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same period last year, the business posted $1.69 earnings per share. The firm's quarterly revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, equities research analysts anticipate that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Analyst Ratings Changes

SOLV has been the subject of a number of analyst reports. Stifel Nicolaus boosted their price objective on shares of Solventum from $90.00 to $100.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Benchmark reiterated a "buy" rating on shares of Solventum in a report on Thursday, October 8th. Piper Sandler lifted their price target on shares of Solventum from $92.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Jefferies Financial Group reissued a "buy" rating on shares of Solventum in a research report on Thursday, October 8th. Finally, BMO Capital Markets started coverage on shares of Solventum in a report on Wednesday, July 8th. They issued a "market perform" rating and a $81.00 price target for the company. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $92.80.

Solventum Profile

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products, technologies and services designed to support clinical care, healthcare operations and patient outcomes. The company serves healthcare providers, dental professionals, laboratories, manufacturers and other organizations.

Solventum's portfolio includes medical and surgical products such as wound-care systems, surgical drapes, sterilization and infection-prevention solutions, and patient-monitoring or fixation products.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.